Liver Carcinogenesis Suppression in Chronic Hepatitis B in the Nucleoside Analogues Era
In Vivo · 2024
DOI: 10.21873/invivo.13408 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift In Vivo, 2024. Verfasst von Hiroki Nishikawa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan; hiroki.nishikawa@ompu.ac.jp. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan; hiroki.nishikawa@ompu.ac.jp.
- Premier Departmental Research of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
- Department of Gastroenterology, Kobe Asahi Hospital, Kobe, Japan.
- Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Zitieren
APA
Nishikawa, H., Kim, S. K., & Asai, A. (2024). Liver Carcinogenesis Suppression in Chronic Hepatitis B in the Nucleoside Analogues Era. In Vivo. https://doi.org/10.21873/invivo.13408
Vancouver
Nishikawa H, Kim SK, Asai A. Liver Carcinogenesis Suppression in Chronic Hepatitis B in the Nucleoside Analogues Era. In Vivo. 2024. doi:10.21873/invivo.13408
BibTeX
@article{Nishikawa2024,
author = {Nishikawa, Hiroki and Kim, Soo Ki and Asai, Akira},
title = {Liver Carcinogenesis Suppression in Chronic Hepatitis B in the Nucleoside Analogues Era},
journal = {In Vivo},
year = {2024},
doi = {10.21873/invivo.13408}
}
EUVIMED